Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma - Concepedia

Concepedia

Publication | Open Access

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

DOI Full Paper Access

387

Citations

29

References

2000

Year

Olga Lyass, Beatrice Uziely, Rami Ben‐Yosef, Dinah Tzemach, Norman I. Heshing, Michal Lotem, G Brufman, Alberto Gabizon

Abstract

The toxicity of Doxil is dose and schedule dependent and well correlated with pharmacokinetic parameters. Pharmacokinetic guidance of Doxil dosing may be a useful tool.

References

	Year	Citations
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure Daniel D. Von Hoff Annals of Internal Medicine Drug SafetyPotential Risk FactorsHeart FailureHealth SciencesCardiovascular Disease	1979	2.4K
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Alberto Gabizón, Raphael Catane, Beatrice Uziely, PubMed EngineeringCirculation TimePathologyDoxorubicin MetabolitesExtracellular Microvesicles	1994	1.4K
Dermatology in General Medicine Philip C. Anderson JAMA BiologyElegant TextbookThomas FitzpatrickPathologyMedical History	1994	1.2K
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Fan Yuan, Michael Leunig, S.K. Huang, PubMed Microvascular PermeabilityEngineeringExtracellular MicrovesiclesEffective PermeabilityInterstitial Penetration	1994	912
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Franco M. Muggia, John D. Hainsworth, Susan Jeffers, Journal of Clinical Oncology	1997	656
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. Donald W. Northfelt, Bruce J. Dezube, James Thommes, Journal of Clinical Oncology Pegylated-liposomal DoxorubicinMedicineImmunologyPharmacologyPathology	1998	639
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Ronald G. Schwartz, W. Mckenzie, J. Steven Alexander, The American Journal of Medicine CardiomyopathyHeart FailureStructural Heart DiseaseCardiovascular DiseaseCardiovascular Pharmacology	1987	511
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. Beatrice Uziely, Susan Jeffers, Rut Isacson, Journal of Clinical Oncology	1995	476
Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Ning Wu, T L Rudoll, David Needham, PubMed EngineeringExtracellular MicrovesiclesBiomedical EngineeringLipid MovementCellular Physiology	1993	366
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. Sherry H. Stewart, H Jablonowski, F. D. Goebel, Journal of Clinical Oncology	1998	357

Page 1